• Multifocal primary uveal melanoma is a rare entity with known clinical risk factor of underlying ocular melanocytosis and genetic risk factor with BAP1 mutation.
documented choroidal nevus, and after undergoing enucleation, there was no detectable connection between the tumors on histopathologic examination. Germline BAP1 mutation was absent in both cases. Multifocal primary uveal melanoma is a rare entity in which the second tumor may occur either de novo or from a malignant transformation of a choroidal nevus. Known risk factors include ocular melanocytosis or germline BAP1 mutation. Additional underlying mechanisms have yet to be elucidated.
Introduction
Uveal melanoma is the most common primary cancer of the eye in adults, and it almost always presents as a unilateral, unifocal tumor. Bilateral uveal melanoma has been reported, with an estimated lifetime risk of 1 in 50 million, whereas unilateral, multifocal uveal melanoma appears to be even rarer [1] [2] [3] [4] . Very few cases of unilateral multifocal uveal melanoma have been reported [5] [6] [7] . Some reported cases occurred in the setting of ocular melanocytosis, which strongly predisposes to uveal melanoma [8] . Herein, we report 2 patients with pathologically confirmed multifocal uveal melanoma that occurred in the absence of ocular melanocytosis, cutaneous melanoma, or familial cancer syndrome [9] . One patient underwent molecular analysis by gene expression profiling of the second tumor, and both underwent BAP1 germline mutational analysis.
Case Report

Case 1
A 75-year-old white male presented to our clinic 9 years after undergoing iodine-125 plaque brachytherapy with supplemental transpupillary thermotherapy in the right eye for a macular choroidal melanoma extending into the inferotemporal mid-periphery. Treatment and subsequent follow-up had been performed outside our institution. On examination, the tumor remained regressed with no local recurrence (Fig. 1a) . However, a distinct pigmented choroidal tumor was detected in the superonasal periphery measuring 8.0 × 6.5 mm in basal dimensions and 2.6 mm in thickness (Fig. 1b) . There was an area of normal choroid separating the first and second tumors, with no perceptible connection between them (Fig. 1c) . Transscleral fine needle aspiration biopsy of the second tumor confirmed choroidal melanoma ( Fig. 1d ) with a Class 2 gene expression profile. Sequencing of DNA from peripheral blood lymphocytes revealed no evidence of germline BAP1 mutation (CLIA, Prevention Genetics) to suggest a familial melanoma predisposition. He had no family history of cancer. The patient refused enucleation, so the second tumor was treated with iodine-125 plaque brachytherapy. He died of esophageal carcinoma 19 months after the treatment of the second tumor.
Case 2
A 50-year-old male initially complained of a black spot in his visual field, which led to the discovery of a medium-sized ciliochoroidal malignant melanoma located inferiorly at the 4: 30 to 7: 00 o'clock position in his right eye. The tumor measured 16.0 × 14.0 mm in basal diameter and 7.5 mm in thickness and was treated with iodine-125 plaque brachytherapy, showing tumor regression after 9 years of postoperative follow-up. He was diagnosed with radiation retinopathy and neovascular glaucoma along the course of his follow-up and was treated with panretinal photocoagulation and intravitreal bevacizumab, and a glaucoma drainage implant was placed for intraocular pressure control. On his annual visit 9 years after radiation therapy, his regressed tumor was stable with atrophic margins (Fig. 2a) . However, a new melanocytic tumor was identified underlying the macula and extending into the superotemporal mid-periphery, measuring 13.0 × 12.5 × 5.3 mm, with associated orange pigmentation and subretinal fluid (Fig. 2b) . This tumor corresponded with a previously described choroidal nevus, which had been measured by ultrasonography at 8.5 × 8.5 × 2.2 mm during the last annual visit (Fig. 2c) . Given the patient's poor visual prognosis (longstanding visual acuity of hand motion) and neovascular glaucoma, the patient's eye was enucleated. Histopathology confirmed the diagnosis of a second, independent choroidal malignant melanoma, which showed no anatomic relationship with the initial irradiated melanoma (Fig. 2d) . This case of multifocal choroidal melanoma has the unique feature of the second tumor arising from a malignant transformation of a choroidal nevus. Genetic testing showed no germline BAP1 mutation (CLIA, Prevention Genetics). The patient had no relevant family history of cancer.
Discussion
Our two patients were diagnosed with the second uveal melanoma 9 years after treatment of their initial choroidal melanoma. Clinical features and histopathology indicate that the second lesion did not appear to be continuous with the first melanoma in the patient for which a globe enucleation specimen was obtained for histologic examination. Although it is possible that a single uveal melanoma may be diffuse and multinodular with contiguous spread giving the false impression of multifocal melanoma, this is unlikely to be the case in our patients given the location and time interval between presentations, as the recurrences tend to be marginal and occur within the first 5 years after initial treatment [10] . Furthermore, gonioscopy and histological analysis excluded the possibility of occult ring melanoma or contiguous melanoma [11] .
Systemic workup was performed in both cases and did not reveal a non-ocular primary (such as cutaneous or mucosal melanoma) as the source of metastases to the choroid. Another possibility would be that the second tumor is a metastasis of the first tumor. Although metastatic choroidal melanoma to the contralateral choroid has been reported, ipsilateral choroidal metastasis is highly unlikely given the absence of systemic (hepatic) metastasis [12] . In addition, none of our tumors had germline BAP1 mutation [13] .
In the past, the presence of oculodermal melanocytosis mainly in Caucasian patients was the only known risk factor for developing multifocal uveal melanoma, with a 30-fold greater risk to develop a uveal melanoma than in the general population [8, [14] [15] [16] . None of our patients had DOI: 10.1159/000487891 evidence of oculodermal melanocytosis, dysplastic nevus syndrome, or neurofibromatosis type 1 [17] . Additionally, none reported occupational risk factors such as increased UV exposure from arc welding or exposure to industrial toxins [18, 19] .
A possible clinical risk factor for multifocal uveal melanoma may be the presence of a concomitant choroidal nevus at initial presentation that later transformed into a second uveal melanoma, which was the case in one of our patients. Only a limited number of cases have been reported [5, 20, 21] . Such an occurrence would be rare given the low risk of malignant transformation of a choroidal nevus [5, 22] . The role of radiation exposure from the plaque brachytherapy that delivered 88 Gy to the first tumor located in inferior periphery in inducing malignant transformation of the nevus superotemporal to the macula remains speculative. Using plaque simulator treatment planning software (Plaque Simulator v 5.3.4; Bebig GmbH, Berlin, Germany) it can be estimated that the location of the nevus received approximately 27 Gy, intervening uvea received more than 27 Gy, and the uvea beyond the nevus received less than 27 Gy, and yet the second melanoma arose at the site of the preexisting nevus. The existence of a genetic risk factor for the development of multifocal uveal melanoma can be suspected. In recent years, BAP1 mutation has been suggested as both a risk factor for uveal melanoma metastasis, as well as for the development of uveal melanoma within a germline BAP1 mutation tumor syndrome, which also includes mesothelioma, skin melanoma, and renal cell carcinoma [9, [23] [24] [25] . Furthermore, the possible relationship between germline BAP1 mutation and multifocal uveal melanoma has been suggested [7] . However, germline BAP1 mutation was absent in both of our cases. Other germline mutations (BRCA2, P16(INK4A), P14(ARF), and P15) associated with uveal melanoma development were not investigated in our cases [26] . The lack of known predisposing clinical or suspected genetic risk factors in our two patients suggests that there are as yet unidentified underlying risk factors for the development of multifocal uveal melanoma that remain to be elucidated. Although the risk of an additional tumor developing in a patient who has already had a primary uveal melanoma is low, careful periodic examination and ultrasonography is required, especially in patients with known coexisting choroidal nevi or oculodermal melanocytosis.
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